V Surmont

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Lessons to learn from EORTC study 08981: a feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3008 AE Rotterdam, The Netherlands
    Lung Cancer 55:95-9. 2007
  2. ncbi Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Lung Cancer 66:333-7. 2009
  3. ncbi A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncology 78:267-70. 2010
  4. ncbi [Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study]
    A N van Geel
    Erasmus MC, Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam
    Ned Tijdschr Geneeskd 151:1406-11. 2007
  5. ncbi Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Oncol 2009:457418. 2009
  6. ncbi A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer
    J G J V Aerts
    Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands
    J Thorac Oncol 1:532-6. 2006

Detail Information

Publications6

  1. ncbi Lessons to learn from EORTC study 08981: a feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3008 AE Rotterdam, The Netherlands
    Lung Cancer 55:95-9. 2007
    ..Though evident, the feasibility to complete this kind of studies within a reasonable time period is still a condition sine qua non...
  2. ncbi Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Lung Cancer 66:333-7. 2009
    ..Oral treatment regimens with few side effects are appealing in the 2nd or 3rd line treatment of non-small cell lung cancer (NSCLC) patients...
  3. ncbi A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncology 78:267-70. 2010
    ..The aim of this study is to investigate whether toxicity of gemcitabine/carboplatin could be reduced by administering carboplatin on day 8 instead of day 1 without a decrease in response rate (RR)...
  4. ncbi [Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study]
    A N van Geel
    Erasmus MC, Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam
    Ned Tijdschr Geneeskd 151:1406-11. 2007
    ....
  5. ncbi Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study
    V Surmont
    Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Oncol 2009:457418. 2009
    ....
  6. ncbi A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer
    J G J V Aerts
    Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands
    J Thorac Oncol 1:532-6. 2006
    ..The objectives of this trial were to evaluate the activity and safety of gemcitabine carboplatin as induction therapy in patients with locally advanced non-small cell lung cancer..